VA and HHS Sign Agreement to Expand Psychedelic Therapy Research for Veterans
On July 14, 2026, the U.S. Departments of Veterans Affairs (VA) and Health and Human Services (HHS) signed a memorandum of understanding to boost research into psychedelic drugs for treating veterans’ mental health disorders, including PTSD, depression, and substance abuse. The agreement follows an April 2026 executive order by President Trump directing the FDA to accelerate psychedelic treatment reviews, with at least $50 million committed to ibogaine research. It aims to expand clinical trials, train medical staff, and collect regulatory data. VA researchers are involved in over 20 trials on MDMA and psilocybin.
Editorial responsibility
- No named human review is recorded for this page.
- Reports are grouped by semantic similarity and deterministic rules. Language models may assist titles, summaries, translation and cross-source analysis; the page itself is projected from evidence records.
- Source updates only; analysis pending
Analysis pending
Cross-source coverage
Wire timeline
VA and HHS Sign Agreement to Expand Psychedelic Therapy Research for Veterans' Mental Health
The Departments of Veterans Affairs (VA) and Health and Human Services (HHS) signed a memorandum of understanding on July 15, 2026, to increase coordination on research into psychedelic drugs for treating veterans' mental health disorders, including PTSD, depression, and substance abuse. The agreement follows an April 2026 executive order by President Donald Trump directing the FDA to accelerate review of psychedelic treatments, with at least $50 million committed to ibogaine research. The VA will expand clinical trial participation, train therapists to administer psychedelics if approved, and collect data for regulators. VA researchers are involved in over 20 trials on MDMA and psilocybin. A separate $4.9 million DoD study is ongoing at Walter Reed on MDMA for PTSD. The FDA rejected MDMA approval in 2024, citing need for more safety and efficacy data. A RAND study found 4.8 million U.S. veterans have used psychedelics, with LSD and psilocybin being most common.
VA and HHS Sign Agreement to Expand Psychedelic Therapy Research for Veterans
The Departments of Veterans Affairs (VA) and Health and Human Services (HHS) signed a memorandum of understanding on July 15, 2026, to increase coordination on research into psychedelic drugs for treating veterans' mental health disorders, including PTSD, depression, and substance abuse. The agreement follows an April 2026 executive order by President Donald Trump directing the FDA to accelerate review of psychedelic treatments, with at least $50 million committed to ibogaine research. The VA will expand clinical trial participation, train therapists to administer psychedelics if approved, and collect data to support regulatory decisions. VA researchers are involved in over 20 trials on MDMA, psilocybin, and other substances. The Defense Department is also conducting a $4.9 million study at Walter Reed on MDMA for PTSD. A RAND study found 4.8 million veterans have used psychedelics, and many have sought treatment abroad due to limited domestic options. The FDA rejected MDMA for PTSD in 2024, citing need for more safety and efficacy data.
VA and HHS sign agreement to expand psychedelic therapy research for veterans
The Departments of Veterans Affairs (VA) and Health and Human Services (HHS) signed a memorandum of understanding on July 13, 2026, to increase coordination on research into psychedelic drugs for treating veterans' mental health disorders, including PTSD, depression, and substance abuse. The agreement follows an April 2026 executive order by President Donald Trump directing the FDA to accelerate review of psychedelic treatments, with at least $50 million committed to ibogaine research. The VA and FDA also signed a separate collaboration agreement. VA researchers are involved in over 20 trials on MDMA, psilocybin, and other psychedelics. A RAND study estimates 4.8 million American veterans have used psychedelics. The FDA rejected MDMA for PTSD treatment in 2024, citing need for more safety and efficacy data. Veterans advocate Ron Adkins emphasized the need for innovative, accessible treatments.
Show 12 older updatesHide older updates
VA and HHS Sign Agreement to Expand Psychedelic Therapy Research for Veterans
The Departments of Veterans Affairs (VA) and Health and Human Services (HHS) signed a memorandum of understanding on July 13, 2026, to increase coordination on research into psychedelic drugs for treating veterans' mental health disorders, including PTSD, depression, and substance abuse. The agreement aims to expand clinical trial participation, train medical staff to administer psychedelics if federally approved, and collect data to support regulatory decisions. It follows an April 2026 executive order by President Trump directing the FDA to accelerate review of psychedelic treatments, with at least $50 million committed to ibogaine research. VA researchers are involved in over 20 trials on MDMA and psilocybin. The Defense Department is also conducting a $4.9 million MDMA study at Walter Reed. A RAND study found 4.8 million veterans have used psychedelics. The FDA rejected MDMA for PTSD in 2024, citing need for more safety and efficacy data.
VA and HHS Sign Agreement to Expand Psychedelic Therapy Research for Veterans
The Departments of Veterans Affairs (VA) and Health and Human Services (HHS) signed a memorandum of understanding on July 15, 2026, to increase coordination on research into psychedelic drugs for treating veterans' mental health disorders, including PTSD, depression, and substance abuse. The agreement aims to expand clinical trial participation, train medical staff to administer psychedelic medications if federally approved, and collect data to support regulatory decisions. This follows an April 2026 executive order by President Donald Trump directing the FDA to accelerate review of psychedelic treatments, with at least $50 million committed to ibogaine research. VA researchers are involved in over 20 trials on MDMA and psilocybin. A RAND study estimates 4.8 million American veterans have used psychedelics. The FDA rejected MDMA for PTSD in 2024, citing need for more safety and efficacy data. The agreement was praised by veterans advocates as a step toward innovative mental health care.
VA and HHS Sign Agreement to Expand Psychedelic Therapy Research for Veterans
The Departments of Veterans Affairs (VA) and Health and Human Services (HHS) signed a memorandum of understanding on July 15, 2026, to increase coordination on research into psychedelic drugs for treating veterans' mental health disorders, including PTSD, depression, and substance abuse. The agreement aims to expand clinical trial participation, train medical staff to administer psychedelics if federally approved, and collect data to support regulatory decisions. It follows an April 2026 executive order by President Donald Trump directing the FDA to accelerate review of psychedelic treatments, with at least $50 million committed to ibogaine research. VA researchers are involved in over 20 trials on MDMA and psilocybin. A RAND study found that 4.8 million American veterans have used psychedelics. The FDA rejected MDMA for PTSD in 2024, but a new VA study is underway in Providence, Rhode Island. Veteran advocates emphasized the need for innovative, accessible treatments.
VA and HHS Sign Agreement to Expand Psychedelic Therapy Research for Veterans
The Departments of Veterans Affairs (VA) and Health and Human Services (HHS) signed a memorandum of understanding on July 15, 2026, to increase coordination on research into psychedelic drugs for treating veterans' mental health disorders, including PTSD, depression, and substance abuse. The agreement aims to expand clinical trial participation, train medical staff to administer psychedelic medications if federally approved, and collect data to support regulatory decisions. This follows an April 2026 executive order by President Trump directing the FDA to accelerate review of psychedelic treatments, with at least $50 million committed to ibogaine research. VA researchers are involved in over 20 trials on MDMA, psilocybin, and other psychedelics. A RAND study found that nearly 5 million American veterans have used psychedelic drugs. The FDA previously rejected MDMA for PTSD treatment in 2024, citing need for more safety and efficacy data. Veterans advocate Ron Adkins emphasized the need for innovative, accessible treatments.
VA and HHS sign agreement to expand psychedelic therapy research for veterans' mental health
The Departments of Veterans Affairs (VA) and Health and Human Services (HHS) signed a memorandum of understanding on July 15, 2026, to increase coordination on research into psychedelic drugs for treating veterans' mental health disorders, including PTSD, depression, and substance abuse. The agreement follows an April 2026 executive order by President Trump directing the FDA to accelerate review of psychedelic treatments, with at least $50 million committed to ibogaine research. The VA is involved in over 20 clinical trials on MDMA, psilocybin, and other psychedelics. The Defense Department is also conducting a $4.9 million study at Walter Reed on MDMA for PTSD. A RAND study found that nearly 5 million veterans have used psychedelics. The FDA rejected MDMA for PTSD in 2024, citing need for more safety and efficacy data. Veterans advocate Ron Adkins emphasized the need for innovative, accessible treatments.
VA and HHS sign agreement to expand psychedelic therapy research for veterans' mental health
The Departments of Veterans Affairs (VA) and Health and Human Services (HHS) signed a memorandum of understanding on July 14, 2026, to increase coordination on research into psychedelic drugs for treating veterans' mental health disorders, including PTSD, depression, and substance abuse. The agreement aims to expand clinical trial participation, train medical professionals to administer psychedelic medications if federally approved, and collect data for regulators. It follows an April 2026 executive order by President Donald Trump directing the FDA to accelerate review of psychedelic treatments, with at least $50 million committed to ibogaine research. VA researchers are involved in over 20 trials on MDMA and psilocybin. A RAND study found an estimated 4.8 million American veterans have used psychedelic drugs. The FDA rejected MDMA for PTSD treatment in 2024, citing need for more safety and efficacy data.
VA and HHS Sign Agreement to Expand Psychedelic Therapy Research for Veterans
The Departments of Veterans Affairs (VA) and Health and Human Services (HHS) signed a memorandum of understanding on July 14, 2026, to increase coordination on research into psychedelic drugs for treating veterans' mental health disorders, including PTSD, depression, and substance abuse. The agreement follows an April 2026 executive order by President Donald Trump directing the FDA to accelerate review of psychedelic treatments, with at least $50 million committed to ibogaine research. The MOU aims to increase clinical trial participation, train medical staff to administer psychedelics if approved, and collect data for regulators. VA researchers are involved in over 20 trials on MDMA and psilocybin. A RAND study found 4.8 million U.S. veterans have used psychedelics. The FDA rejected MDMA for PTSD in 2024, citing need for more research. The agreement also includes a separate VA-FDA collaboration to support therapy development.
VA and HHS sign agreement to expand psychedelic therapy research for veterans' mental health
The Departments of Veterans Affairs (VA) and Health and Human Services (HHS) signed a memorandum of understanding on July 14, 2026, to increase coordination on research into psychedelic drugs for treating veterans' mental health disorders, including PTSD and depression. The agreement aims to expand clinical trial participation, train medical professionals to administer psychedelic medications if federally approved, and collect data to support regulatory decisions. This follows an April 2026 executive order by President Donald Trump directing the FDA to accelerate review of psychedelic treatments, with at least $50 million committed to ibogaine research. The VA is currently involved in over 20 research trials on MDMA and psilocybin. A RAND study found that nearly 5 million American veterans have used psychedelic drugs. The FDA previously rejected MDMA for PTSD treatment in 2024, citing insufficient safety and efficacy data.
VA and HHS Sign Agreement to Expand Psychedelic Therapy Research for Veterans
The Departments of Veterans Affairs (VA) and Health and Human Services (HHS) signed a memorandum of understanding on July 14, 2026, to boost coordination on research into psychedelic drugs for treating veterans' mental health disorders, including PTSD, depression, and substance abuse. The agreement aims to increase clinical trial participation, train medical staff to administer psychedelics if federally approved, and collect data for regulators. It follows an April 2026 executive order by President Donald Trump directing the FDA to accelerate review of psychedelic treatments, with at least $50 million committed to ibogaine research. VA researchers are involved in over 20 trials on MDMA and psilocybin. A RAND study found 4.8 million U.S. veterans have used psychedelics. The FDA rejected MDMA for PTSD in 2024, citing need for more safety and efficacy data. Veterans advocate Ron Adkins stressed the need for innovative treatments tailored to individual mental health needs.
VA and HHS Sign Agreement to Expand Psychedelic Therapy Research for Veterans
The Departments of Veterans Affairs (VA) and Health and Human Services (HHS) signed a memorandum of understanding on July 15, 2026, to increase coordination on research into psychedelic drugs for treating veterans' mental health disorders, including PTSD, depression, and substance abuse. The agreement aims to expand clinical trial participation, train medical professionals to administer psychedelic medications if federally approved, and collect data to support regulatory decisions. This follows an April 2026 executive order by President Donald Trump directing the FDA to accelerate review of psychedelic treatments, with at least $50 million committed to ibogaine research. VA researchers are involved in over 20 trials on MDMA and psilocybin. A RAND study found an estimated 4.8 million American veterans have used psychedelic drugs. The FDA rejected MDMA approval in 2024, citing need for more safety and efficacy data. The agreement was praised by veterans advocates as a step toward innovative mental health treatments.
VA and HHS Sign Agreement to Expand Psychedelic Therapy Research for Veterans
The Departments of Veterans Affairs (VA) and Health and Human Services (HHS) signed a memorandum of understanding on July 14, 2026, to increase coordination on research into psychedelic drugs for treating veterans' mental health disorders, including PTSD, depression, and substance abuse. The agreement aims to expand clinical trial participation, train medical staff to administer psychedelic medications if federally approved, and collect data to support regulatory decisions. This follows an April 2026 executive order by President Trump directing the FDA to accelerate review of psychedelic treatments, with at least $50 million committed to ibogaine research. VA researchers are involved in over 20 trials on MDMA and psilocybin. The FDA rejected MDMA for PTSD in 2024, citing need for more safety and efficacy data. A RAND study found 4.8 million U.S. veterans have used psychedelics. Veterans advocate Ron Adkins emphasized the need for innovative, accessible treatments.
VA and HHS Sign Agreement to Expand Psychedelic Therapy Research for Veterans
The Departments of Veterans Affairs (VA) and Health and Human Services (HHS) signed a memorandum of understanding on July 15, 2026, to increase coordination on research into psychedelic drugs for treating veterans' mental health disorders, including PTSD, depression, and substance abuse. The agreement follows an April 2026 executive order by President Trump directing the FDA to accelerate review of psychedelic treatments, with at least $50 million committed to ibogaine research. The VA will increase clinical trial participation, train therapists to administer psychedelics if approved, and collect data to support regulators. VA researchers are involved in over 20 trials on MDMA and psilocybin. The Defense Department is also conducting a $4.9 million MDMA study at Walter Reed. A RAND study found 4.8 million veterans have used psychedelics. The FDA rejected MDMA for PTSD in 2024, citing need for more research. Veterans advocate Ron Adkins emphasized the need for innovative, accessible treatments.